SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide financial results for the second quarter ended June 30, 2024, on August 1, 2024. The Company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on August 1, 2024.
Financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at . Participants may access the conference call via webcast on the Events & Presentations page of Vir's website at or listen in by dialing the U.S. toll free number (800) 715-9871 or international +1 (646) 307-1963, Conference ID: 7568777. A recorded version of the call will be available on the website approximately two hours after the completion of the event and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses, and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
Media
Carly Scaduto
Senior Director, External Communications
cscaduto@vir.bio
+1 314-368-5189
Investors
Richard Lepke
Senior Director, Investor Relations
rlepke@vir.bio
+1 978-973-9986
Source: Vir Biotechnology, Inc. 旧金山——(BUSINESS WIRE)——Vir生物技术公司(纳斯达克:VIR)今天宣布,该公司将于2024年8月1日公布截至2024年6月30日的第二季度财务业绩,并于同日下午1:30太平洋时间/下午4:30东部时间举行电话会议。
财务业绩将于市场收盘后通过新闻发布,并可在Vir网站的“投资者”中的“新闻稿”下方找到。参与者可以通过Vir网站“活动和演示文稿”页面上的网络广播收听会议或通过拨打美国免费电话号码(800)715-9871或国际电话号码+1(646)307-1963,会议ID:7568777。会议的录音版本将于两小时之后在网站上提供,并在那里档案保留30天。
关于Vir Biotechnology,Inc。
Vir Biotechnology, Inc.是一家免疫学公司,专注于利用关键免疫过程的重要观察结果,让免疫系统发挥作用,通过治疗和预防传染病和其他严重疾病(包括病毒相关疾病)改变生命。Vir已经组建了两个技术平台,旨在调节免疫系统。其目前的临床开发管道包括针对δ型和乙型肝炎病毒以及人类免疫缺陷病毒的产品候选药物。Vir的管道中还有多个临床前候选项目,其中包括针对甲型和乙型流感、COVID-19、RSV / MPV和HPV等的项目。Vir经常在其网站上发布可能对投资者重要的信息。
媒体
Carly Scaduto
通信公关高级董事
cscaduto@vir.bio
+1 314-368-5189
投资者联系
Richard Lepke
投资者关系高级总监
rlepke@vir.bio
+1 978-973-9986
来源:Vir Biotechnology,Inc.